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Organization classification system with
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discovery
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Abstract
Recent updating of the World Health Organization (WHO) classification of central nervous system (CNS) tumors in
2016 demonstrates the first organized effort to restructure brain tumor classification by incorporating histomorphologic
features with recurrent molecular alterations. Revised CNS tumor diagnostic criteria also attempt to reduce interobserver
variability of histological interpretation and provide more accurate stratification related to clinical outcome. As an example,
diffuse gliomas (WHO grades II–IV) are now molecularly stratified based upon isocitrate dehydrogenase 1 or 2 (IDH)
mutational status, with gliomas of WHO grades II and III being substratified according to 1p/19q codeletion status. For
now, grading of diffuse gliomas is still dependent upon histological parameters. Independent of WHO classification criteria,
multidimensional scaling analysis of molecular signatures for diffuse gliomas from The Cancer Genome Atlas (TCGA) has
identified distinct molecular subgroups, and allows for their visualization in 2-dimensional (2D) space. Using the web-based
platform Oncoscape as a tool, we applied multidimensional scaling-derived molecular groups to the 2D visualization of the
2016 WHO classification of diffuse gliomas. Here we show that molecular multidimensional scaling of TCGA data provides
2D clustering that represents the 2016 WHO classification of diffuse gliomas. Additionally, we used this platform to
successfully identify and define novel copy-number alteration-based molecular subtypes, which are independent of
WHO grading, as well as predictive of clinical outcome. The prognostic utility of these molecular subtypes was further
validated using an independent data set of the German Glioma Network prospective glioblastoma patient cohort.
Keywords: Oncoscape, Glioma, Glioblastoma, Astrocytoma, Oligodendroglioma, Isocitrate Dehydrogenase (IDH), World
Health Organization (WHO)
Introduction
For nearly a century, classification of primary brain
tumors has been based solely upon histomorphologic
characteristics and presumed histogenesis of neoplastic
cell types [2, 3]. Early classification systems for diffuse
gliomas relied upon evaluating the histological subtype
as either astrocytoma or oligodendroglioma, with further
histological parameters such as nuclear atypia, mitotic
figures, microvascular proliferation, and necrosis, to
indicate aggressiveness, or higher-grades of gliomas
[2, 20, 34, 38]. Today the most commonly used standard
criteria for classifying gliomas is set forth by the World
Health Organization (WHO). Originally presented in
1979, the WHO classification of central nervous system
(CNS) tumors has been revised in 1993, 2000, 2007, and
most recently in 2016 [23]. Prior to the 2016 classification
system, WHO glioma classification was based solely upon
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histopathological criteria, which contains an inherent
amount of interobserver variability in interpretation,
leading to less predictive clinical outcomes [10, 11, 13, 21,
24, 42]. More recently, large scale genomic efforts such as
those from The Genome Cancer Atlas (TCGA) have led
to a considerable increase in the identification and under-
standing of recurrent genetic and epigenetic alterations
found in diffuse gliomas, WHO grades II–IV, and have
helped to define molecular and prognostic subclasses of
these tumors [7–9, 30, 31, 43, 45, 46]. Such molecular al-
terations include mutations in the isocitrate dehydrogenase
(IDH) 1 and 2 genes, codeletion of chromosome arms 1p
and 19q, or hypermethylation of the gene encoding O-6-
methylguanine DNA methyltransferase (MGMT) [4, 8, 9,
12, 22, 31, 32, 46]. To reflect the understanding of genetic
and genomic contributions to glioma biology, the 2016
WHO classification introduced revised classification
criteria to incorporate traditional histopathology and
molecular signatures into ‘integrated’ diagnostic entities
[23, 25, 26, 33]. Special attention has also been made in
this new version to conceptually restructure glioma classi-
fication to consider all diffuse gliomas (astrocytomas and
oligodendrogliomas) under the common header of “dif-
fuse astrocytic and oligodendroglial tumors” [23]. Within
this category, molecular alterations help to drive WHO
grade II and III diagnoses, and diagnostic entities include
diffuse astrocytoma designated as IDH-mutant or IDH-
wildtype; anaplastic astrocytoma designated as IDH-mutant
or IDH-wildtype; Oligodendroglioma, IDH-mutant, and
1p/19q-codeleted; and anaplastic oligodendroglioma, IDH-
mutant, and 1p/19q-codeleted [23]. Not otherwise specified
(NOS) categories of these entities are also present, but
should be reserved for cases where molecular testing is not
possible or where the results are not conclusive [23].
Another change in the WHO grade II and III diffuse glioma
category is the discouragement of an oligoastrocytoma
diagnosis [23]. In most instances, oligoastrocytoma can be
refined into either the astrocytoma or oligodendroglioma
category based upon molecular information [23, 39].
Glioblastoma, WHO grade IV, is now also classified accord-
ing to IDH status into either glioblastoma, IDH-mutant or
glioblastoma, IDH-wildtype [23]. Histological variants of
glioblastoma, IDH-wildtype include gliosarcoma, giant cell
glioblastoma, and epithelioid glioblastoma. Again, a NOS
designation can be applied in cases of insufficient molecular
information concerning the IDH mutation status.
A recent analysis of molecular signatures of TCGA dif-
fuse glioma datasets by multidimensional scaling (MDS)
showed that there are distinct groups of tumors that
cluster together in 2-Dimensional (2D) space [5]. This
genomic analysis incorporated data from DNA methyla-
tion, DNA copy number alterations (CNAs), and DNA
single nucleotide alterations (SNAs). Major genomic fac-
tors influencing non-biased large clustering of diffuse
gliomas included IDH mutational status, CpG island
methylator phenotype (CIMP), polysomy of chromo-
some 7, monosomy of chromosome 10, and codeletion
of chromosome arms 1p and 19q [5]. Regional grouping
within larger clusters is also seen in association with spe-
cific genetic alterations, such as those in the genes
NRAS, HER2, and TP53. Using this multidimensional
scaling analysis, a web-based, interactive visualization
platform termed Oncoscape [27] was developed for
menu-driven investigation of heterogeneous clinical,
pathological, and molecular parameters of various TCGA
cancer datasets, including diffuse gliomas. Oncoscape, al-
lows users to compare patients across multiple clinical
and genetic features, define trait-based cohorts, align
patients and cohorts along a clinical timeline, perform
integrated statistical analyses, and create high-quality
visualization of integrated clinical and molecular data [27].
In the present study, we leverage Oncoscape to apply 2D
multidimensional scaling analysis of TCGA data to
visualize relevant molecular characteristics related to the
2016 WHO classification of diffuse glioma entities. In
addition, we demonstrated the utility of Oncoscape for ex-
ploring genetically defined subgroups within major diffuse
glioma categories.
Materials and methods
Oncoscape and TCGA data visualization
TCGA point mutation and copy number data for glio-
blastomas as well as WHO grade II and III astrocytic
and oligodendroglial tumors were downloaded from the
University of California Santa Cruz cancer browser
(https://genome-cancer.ucsc.edu/). Classic multidimen-
sional scaling (MDS) of molecular data was performed
as previously described [5]. The minimal TCGA tumor
purity has been reported at 60-80%, which has been
shown to be sufficient (>50% tumor purity) for robust
detection of cancer-related copy number alterations via
GISTIC 2.0 scores [35], and therefore undersampling of
glioma copy number alterations is not likely to affect
MDS in this study. Clinical data were obtained from the
Genomic Data Commons (GDC) Data Portal from the
National Institutes of Health (NIH) [16]. Data were visu-
alized and analyzed using the interactive browser-based
platform, Oncoscape (https://oncoscape.sttrcancer.org).
Diffuse gliomas from the ‘gliomas (TCGA)’ dataset were
visualized in 2D space with available ‘Markers and
Patients’ analysis tools. To be consistent with our prior
description [5], the MDS layout utilizing ‘all genes’ was
used. The current online version of Oncoscape (https://
oncoscape.sttrcancer.org; accessed on May 12, 2017) of-
fers several different 2D layout options, including 13
MDS layouts and 21 principle component analysis
(PCA) layouts based upon differing combinations of mo-
lecular input (copy numbers alterations, somatic nucleotide
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mutations, and RNAseq gene expression) and nine different
gene sets. Relevant genetic and genomic alterations used
for 2016 WHO diffuse glioma classification were queried in
Oncoscape [23]. Also of interest for comparison, were pre-
vious 2007 histopathologic classifications and WHO grades
of TCGA datasets [24]. Three main clusters were identified
by MDS, and individual patients were assigned to each
based upon IDH1/2 mutational status and the presence or
absence of 1p/19q codeletion (Additional file 1: Table S1).
TCGA copy number frequency
Using GISTIC2.0 scores, copy number frequencies of
TCGA gliomas were plotted using R software (Version
3.3.2, RProject for Statistical Computing, http://www.r-
project.org/) applying the ‘copynumber’ package (http://
bioconductor.org/packages/copynumber) using 0.5 and
−0.5 as thresholds.
German glioma network validation set
Glioblastoma sample molecular data (n = 284) from the
German Glioma Network (http://www.gliomnetzwerk.de)
were collected along with survival and gene methylation
data as previously described [41]. Copy number alterations
of individual CpG sites were evaluated based on the R
package ‘conumee’ (http://bioconductor.org/packages/conu
mee) applying an adapted algorithm for baseline-
correction. For evaluation of chromosomal segments, the
median of the states of the corresponding probes was com-
puted. Gains and losses were called using thresholds at
−0.1 and 0.1 on a log2-scale as cutoff. For calling of amplifi-
cations and homozygous deletions in genes of interest
thresholds at 0.6 and −0.6 were used. Segment start- and
end-positions refer to reference genome GRCh37/hg19.
Results are restricted to chromosomes 1, 14 and 19 as well
as CDKN2A, CDK4, andMDM2.
Plots and statistics
Statistical analyses were performed using R software
(Version 3.3.2, RProject for Statistical Computing,
http://www.r-project.org/). Kaplan-Meier analysis for
overall survival was performed using the ‘survival’ pack-
age (https://cran.r-project.org/package=survival) with
P-values determined by Cox proportional hazards re-
gression. Multivariate Cox proportional hazards models
including indicated variables were applied utilizing SPSS
statistical software (Version 22.0, IBM). Linear regres-
sion was performed using GraphPad Prism software
(Version 7.02, https://www.graphpad.com/scientific-soft
ware/prism).
Results
Visualizing WHO diffuse glioma classification
Initially, the diffuse glioma TCGA data were visualized
in relation to 2007 WHO classification criteria, including
histopathology and WHO grade (Fig. 1). For each
charted patient point, the dot diameter increases with
increased genetic alterations (Fig. 1a). Histopathologic
diagnoses as defined by the outdated 2007 WHO classi-
fication of primary brain tumors (oligodendroglioma,
astrocytoma, oligoastrocytoma, glioblastoma) are not
molecular cluster-specific, as each cluster contains a
variable amount of histopathologic heterogeneity
(Fig. 1b). This highlights the issue addressed by the
current 2016 WHO classification, i.e. that histopatho-
logic criteria alone are not entirely representative of gen-
etic alterations in diffuse gliomas, and that the new
WHO classification of integrating histopathology with
molecular studies can be more reproducible for diagnos-
tic purposes.
Therefore, we also queried patient clusters for genetic
changes corresponding to those used for the ‘integrated’
2016 WHO classification of diffuse gliomas (Fig. 2).
Presence of mutated IDH1/2 characterizes two main
clusters, and is absent from the third cluster (Fig. 2a).
Mutated IDH1 is more common and more evenly dis-
persed than mutated IDH2. TP53 and ATRX mutations
occur mostly in one of the IDH-mutant clusters
(Fig. 2b,c). The other IDH-mutant cluster exclusively
harbors 1p/19q codeletion (Fig. 2d). Mutations in IDH2
are seen more frequently in the 1p/19q-codeleted cluster
(Fig. 2b), and appear to have regional grouping as well,
indicating a unique type of DNA structure for these
types of gliomas. Consistent with prior reports [39, 40, 44],
1p chromosomal deletion was more cluster specific than
19q chromosomal deletion. WHO grades II–IV are seen in
both clusters without 1p/19q codeletion, consistent with
the concept that there are no WHO grade IV oligodendro-
gliomas [15, 28]. This observation also supports the re-
moval of glioblastoma with oligodendroglial component as
a distinct diagnostic entity [18]. Taken together, these three
clusters can be designated based upon the 2016 WHO clas-
sification criteria as follows: 1) Oligodendroglial tumors,
IDH-mutant, and 1p/19q-codeleted (WHO grades II–III)
(n = 176); 2) Astrocytic gliomas/glioblastoma, IDH-
mutant (WHO II–IV) (n = 251); and 3) Astrocytic
gliomas/glioblastoma, IDH-wildtype (WHO grades II–
IV) (n = 351) (Fig. 3).
Cluster demographics
Comparison of survival between and within the major
diffuse glioma molecular clusters reflects the improved
and revised 2016 WHO classification system (Fig. 4a, b)
[23]. Comparison of the three molecular clusters defined
by MDS demonstrates and confirms prognostic effect of
IDH mutations, which is further stratified by 1p/19q
codeletion status (Fig. 4b) [8, 9, 23, 26, 30–32, 40].
When looking at WHO grade IV glioblastomas, the tu-
mors within the IDH-mutant cluster are associated with
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longer survival than tumors within the IDH-wildtype
cluster, again consistent with prior studies of glioblast-
oma and the new WHO classifications [4, 17, 23, 26, 30,
46]. There are some caveats in trying to interpret sur-
vival studies from this TCGA data, especially for the
WHO grade II and III diffuse gliomas, as availability of
outcome data was not a main factor in selecting cases.
WHO grade II and III diffuse glioma patients have lon-
ger survival than glioblastoma patients, and therefore re-
quire longer clinical follow up. In addition to survival,
age at diagnosis was shown to vary between clusters
(Fig. 4c–e). The astrocytic glioma/glioblastoma, IDH-
wildtype cluster has the oldest age distribution peak,
occurring at 56–63 years (Fig. 4c). By contrast, the astro-
cytic glioma/glioblastoma, IDH-mutant cluster has the
youngest age distribution peak, occurring at 26–32 years
(Fig. 4d). The oligodendroglial tumor cluster shows a
distribution in adults with two peak ages at diagnosis at
35–41 and 53–59 year age ranges, with a median age of
45 years (Fig. 4e). The association of age within the 2016
WHO definition of IDH-mutant and 1p/19q-codeleted
oligodendroglial tumors has not been described. To in-
vestigate associations of this bimodal age distribution
with overall survival, the oligodendroglial tumor cluster
was subdivided into two groups utilizing median age at
diagnosis (45 years) as a cut-off (Fig. 4f ). Kaplan-Meier
survival analysis demonstrated similar survival curves
when divided either by age or WHO grade (Fig. 4f-h).
Additionally, hazard ratios were prognostic in a Cox re-
gression model containing age <45 versus ≥45 (hazard
ratio [HR]0.137, 95% confidence interval [CI] 0.024–
0.774, p = 0.024), WHO grade II versus grade III (hazard
ratio [HR]0.200, 95% confidence interval [CI] 0.051–
0.791, p = 0.022) and Karnofsky performance score
90–100% versus <90% (hazard ratio [HR]0.167, 95% con-
fidence interval [CI] 0.042–0.660, p = 0.011).
Global copy number alterations of MDS clusters
To add to the current WHO genetic classifiers of IDH
mutation and 1p/19q codeletion, global copy number al-
teration (CNA) frequencies were analyzed across the
molecular clusters defined by MDS to confirm known
CNAs as well as identify new cluster-associated CNAs
(Fig. 5). The oligodendroglial tumor cluster is defined by
the presence of 1p/19q codeletion and the second most
frequent alteration (~25%) is loss of chromosome 4.
Other CNAs across oligodendrogliomas include low-
level gains (chromosomes 7, 8, 11, 16, 17, 20, 21, and 22)
Fig. 1 2D multidimensional scaling plots of TCGA diffuse glioma patients based on genomic data. a Multidimensional scaling shows that there
are three main clusters. b 2007 WHO histopathological classification across the three main clusters (number of cases for each cluster is listed).
c WHO grades are shown across clusters (number of cases for each cluster is listed). d 3D representation of WHO grading, reflecting progression
of each cluster
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and low-level losses (chromosomes 6, 9, 10, 12, 13, 14,
15, 18, and 22) of uncertain significance. The astrocytic
glioma/glioblastoma, IDH-mutant cluster appears more
heterogeneous with respect to CNA than the other
clusters. It has several low- to mid-level CNAs, but un-
like the other clusters, no alteration was present in >50%
of the cluster. Some of the mid-level CNAs include
known astrocytoma-associate alterations such as 9p loss,
Fig. 2 2D diffuse glioma plots with accompanying chromosomal ideograms. a The two main clusters on the right contain mutations in the IDH1
and IDH2 genes, as shown by the purple edges connecting the gene with corresponding patients. The IDH-mutant upper right cluster also carries
the majority of (b) TP53 and (c) ATRX gene mutations. d The IDH-mutant lower right cluster contains gliomas that harbor the oligodendroglioma-specific
1p/19q codeletion, as demonstrated by orange edges connecting low level copy loss chromosomal regions with corresponding affected patients. This
cluster also contains a majority of the IDH2 mutations
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Fig. 3 2D visualization of the revised 2016 WHO classification of diffuse gliomas. Multidimensional scaling demonstrates three major clusters of
diffuse gliomas. The 2007 WHO histopathologic classifiers are heterogeneous and non-specific with regards to the three main clusters. The 2016
WHO classification aligns well with the three major clusters and can be divided into: 1) oligodendroglial tumors, IDH-mutant and 1p/19q-codeleted
(WHO grades II–III); 2) astrocytic gliomas/glioblastomas, IDH-mutant (WHO grades II–IV); and 3) astrocytic gliomas/glioblastomas, IDH-wildtype (WHO
grades II–IV)
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10q loss, and 19q loss [6, 36]. Gain of chromosome 7 is
also present in tumors of the astrocytic glioma/glio-
blastoma, IDH-mutant cluster, but not as frequently
as in the corresponding astrocytic glioma/glioblast-
oma, IDH-wildtype cluster. Regardless of IDH status,
astrocytic glioma/glioblastoma patients have low-frequency
amplifications of 12q in the region of CDK4 and MDM2.
Of note, these alterations were not limited to glioblastomas.
The IDH-wildtype diffuse gliomas have frequent chromo-
some 7 gain, chromosome 10 loss, and 9p loss, among
other CNAs. Additional MDS in three dimensions (image
available at http://zager.co/glioma/chart.html) demonstrates
Fig. 4 Clinical characteristics of TCGA diffuse glioma clusters. a Survival curves from 2007 WHO histopathological classification criteria (A = diffuse
astrocytoma, O = oligodendroglioma, OA = oligoastrocytoma, AA = anaplastic astrocytoma, AO = anaplastic oligodendroglioma, AOA = anaplastic
oligoastrocytoma, GBM = glioblastoma). b Survival comparison of three main 2D molecular clusters. c-e Age at diagnosis distribution for each
cluster. Patients with astrocytic glioma/glioblastoma are older at presentation in the (c) IDH-wildtype cluster than in the (d) IDH mutant cluster.
e An apparent bimodal adult age distribution is seen in the oligodendroglioma cluster, with median age of 45 years. f Survival of patients with
tumors of the oligodendroglioma cluster stratified by age (<45 versus ≥45 years) is significantly different (p = 0.0033), and comparable to survival
stratified by WHO grade (g, h). P values determined using Cox proportional hazard regression
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that the IDH-wildtype cluster can be divided spatially into
three subgroups (designated as A–C in Fig. 5). The IDH-
wildtype subgroup A is separated from B and C by
chromosome 1 gain and/or TP53 point mutations [5]. Fur-
thermore, subgroups B and C can be simply distinguished
by chromosome 19 gain. Co-gain of chromosomes 19 and
Fig. 5 Genomic copy number alteration frequency among molecular clusters. Oligodendrogliomas are defined by 1p/19q codeletion and the
second most frequent alteration is loss of chromosome 4. The IDH-mutant astrocytic glioma/glioblastoma cluster has several low level copy
number alterations, including known astrocytoma-associated alterations such as 9p loss and 19q loss. IDH-wildtype diffuse gliomas have frequent
polysomy chromosome 7, chromosome 10 loss, and 9p loss. The IDH-wildtype cluster can be further divided into 3 subgroups (a–c). Subgroup A
is separated from B and C by either the presence of polysomy chromosome 1 or TP53 mutations. Subgroups B and C are further separated by the
presence or absence of polysomy chromosome 19
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20, which has been described in a small series of long-term
glioblastoma survivors [14], is frequently observed in the
IDH-wildtype subgroup B. There is a significant survival
difference (p = 0.034, Cox proportional hazards regression)
between subgroups B and C, which are distinguished
by gain of chromosome 19 (Additional file 1: Figure S1).
Co-amplification of CDK4 and MDM2 further augments
survival in a molecular subgroup-specific manner
(Additional file 1: Figure S1).
Identification and characterization of cluster-derived
molecular subtypes
After evaluation of global CNA frequency across the
astrocytic glioma/glioblastoma clusters, a small number
of cluster-derived CNAs were interrogated for survival
prediction and possible risk-stratification. CNA molecu-
lar subtypes are defined by chromosome 1 gain, chromo-
some 19 gain, and CDK4/MDM2 co-amplification for
the astrocytic glioma/glioblastoma, IDH-wildtype cluster
(W1–W4), as well as CDK4 amplification, CDKN2A
deletion, and chromosome 14 gain for the astrocytic gli-
oma/glioblastoma, IDH-mutant cluster (M1–M3) (Fig. 6).
For the most common type of diffuse glioma, i.e. glio-
blastoma, IDH-wildtype, WHO Grade IV, there is a dif-
ference in overall survival across the W1–W3 molecular
subtypes (p = 0.002, Cox proportional hazards regres-
sion, Fig. 7a), with median overall survival of 6.6 months
(W1), 12.7 months (W2) and 15.2 months (W3), respect-
ively. As these are all WHO grade IV tumors, these
wildtype molecular subtypes are independent of grading.
For the astrocytic glioma/glioblastoma, IDH-mutant
cluster, independent of WHO grade, there is a significant
overall survival difference across the M1–M3 molecular
subtypes (p < 0.001, Cox proportional hazards regres-
sion, Fig. 7b), with median survivals of 23.3 months
(M1), 63.0 months (M2) and 94.5 months (M3). Segrega-
tion by WHO grade was prognostic within the astrocytic
glioma/glioblastoma, IDH-mutant cluster, yielding a me-
dian overall survival of 34.1 months (WHO Grade IV),
68.4 months (WHO Grade III) and 95.8 months (WHO
Grade II), respectively (p = 0.007, Cox proportional haz-
ards regression, Fig. 7b). In patients within the astrocytic
glioma/glioblastoma, IDH-mutant glioma cluster, me-
dian overall survival with WHO grade III/IV versus
WHO grade II was 63.0 versus 95.8 months (p = 0.007,
Cox proportional hazards regression, Fig. 7c). Segrega-
tion of these patients by M1/2 versus M3 molecular sub-
groups yielded similar survival proportions of 51.2
versus 94.5 months (p < 0.001, Cox proportional hazards
regression, Fig. 7c). The association with overall survival
was retained for M1/2 versus M3 upon adjustment for
WHO grade (Hazard ratio [HR] 3.28, 95% confidence
interval [CI] 1.62–6.62, p = 0.001), and vice versa for
WHO grade III/IV versus grade II upon adjustment for
molecular subgroup (HR 2.01, 95% CI 1.06–4.02, p =
0.036, Fig. 7c). Survival curves within the astrocytic gli-
oma/glioblastoma, IDH-mutant cluster based on mo-
lecular subtypes (M1-3) or WHO grade (II–IV) are
somewhat comparable, with a slightly stronger associ-
ation with overall survival for molecular subtyping.
However, molecular classification may be more reliable
than grading between pathologists as the exact criteria
for defining a WHO grade II diffuse astrocytoma versus
WHO grade III anaplastic astrocytoma are not well-
defined for resection material and may be associated
with interobserver variability [1, 23, 26, 29, 42].
Validation of cluster-derived molecular subtypes
To test the potential clinical utility of cluster-derived
molecular subtypes, an independent large validation data
set (n = 284) of glioblastomas from the German Glioma
Network (GGN) was evaluated. Comparing WHO grade
IV glioblastomas, median overall survival of the GGN
cohort (18.9 months) versus the TCGA cohort
(13.5 months) was longer (p < 0.001, Cox proportional
hazards regression). A caveat to this comparison is that
the TCGA gliomas are WHO grade II–IV while the
GGN gliomas are all WHO grade IV, which should not
be a significant confounder as the molecular subtypes
appear to be grade independent (Fig. 7) and in addition,
the GGN data set has longer overall survival. Overall
survival data in the GGN cohort were normalized for
validation to account for the difference in median sur-
vival between the GGN and TCGA cohorts. In the GGN
cohort the W1 and W2 subtypes did not show difference
(p = 0.913, Cox proportional hazards regression) in sur-
vival so their combined median overall survival was used
for baseline normalization. Normalized median overall
survival for each molecular subtype showed similar
trends for TCGA and GGN data sets (Fig. 8a). Addition-
ally, linear regression shows a nearly 1:1 overall ratio
(slope = 0.958, R = 0.899) comparing TCGA and GGN
overall survival by molecular subtypes (Fig. 8b). In sum-
mary, overall survival times of the cluster-derived mo-
lecular subtypes identified in the TCGA discovery set
were comparable in the GGN validation set.
Discussion
Visualization of adult diffuse gliomas by multidimen-
sional analysis represented in Oncoscape provides con-
venient graphical representation of the revised 2016
WHO classification system in 2D space. Three main
Oncoscape clusters represent the new risk-stratification
classification by IDH mutation and 1p/19q codeletion
status. Subgroups based upon additional molecular alter-
ations within these clusters are emerging, but are still
yet to be completely defined [5]. The molecular groups
are not well-reflected by the 2007 WHO histopathological
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criteria alone. In fact, each molecular cluster shows vari-
able heterogeneity of histopathological subtypes of diffuse
gliomas. This observation reinforces the concept of inter-
observer variability of diagnoses based upon histology
alone, and highlights why integrating molecular alterations
in diffuse gliomas increases diagnostic accuracy.
In addition to illustrating the inherent interobserver
variability of histopathologic only classification of diffuse
gliomas, Oncoscape also reflects why the diagnosis of
(mixed) oligoastrocytoma is discouraged in the new
WHO system and how ‘oligoastrocytoma’ easily resolves
into either oligodendroglioma or astrocytoma entities
[13, 23, 33, 37]. If oligoastrocytoma truly existed as a
specific biological entity, these cases would be expected
to exist between the IDH-mutant oligodendroglial and
astrocytic glioma clusters shown in Fig. 1b, however, no
such cases are seen. Furthermore, histopathological ‘oli-
goastrocytoma’ cases are predominantly evenly distributed
and completely embedded within the oligodendroglial
tumor and astrocytic glioma/glioblastoma, IDH-mutant
clusters, further arguing against oligoastrocytoma as a
distinct entity. However, we do note that there are re-
ported rare cases of true oligoastrocytomas with distinct
regions of either molecular oligodendroglioma or as-
trocytoma features [19], and the WHO does allow for
designation of these gliomas as oligoastrocytoma,
NOS [23]. However, where such rare molecular biphe-
notypic cases fall into place on the Oncoscape map
has yet to be determined.
A current area for future clarification and refinement
in the WHO classification system is that of grading [26].
While molecular alterations were incorporated into the
2016 WHO classification system, grading of diffuse
gliomas did not change from the prior 2007 edition
[23, 24, 26]. It appears that molecular alterations are
strong drivers of clinical behavior, and may be considered
as a first stratifier, as IDH-mutant diffuse gliomas clinically
behave better than IDH-wildtype diffuse gliomas across all
grades [4, 8, 17, 23, 26, 31, 32]. For example, determin-
ation of IDH mutational or ‘Oncoscape’ cluster status,
may be considered as baseline diagnostic criteria. After
the baseline diagnosis is established, cluster-specific
Fig. 6 Diagnostic algorithm for 2D-mapping derived, copy number alteration-based, molecular subtypes of diffuse gliomas. Survival represent
TCGA glioma dataset and P values were determined using Cox proportional hazard regression
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grading may be warranted, either histologically or molecu-
larly. On the histologic side, there is some existing litera-
ture that supports this type of molecular stratification
first, followed by grading. Using a specific mitotic index
independent of WHO grading, mitotic counting has been
shown to stratify IDH-wildtype, but not IDH-mutant as-
trocytomas [31]. This suggests that there may be yet to be
determined cluster-specific mitotic indices for future
Fig. 7 Multidimensional scale mapping derived copy number alterations forms unique prognostic molecular subtypes. a Glioblastoma, IDH-wildtype,
WHO grade IV can be divided into three subtypes (W1–3). b The IDH-mutant astrocytic glioma/glioblastoma cluster can be divided into three molecular
subtypes. These molecular subtypes are reflective of overall survival, and independent of WHO grade. c Dividing the molecular subtypes into either poor
(M1/M2) or favorable (M3) groups is significantly associated with survival (Hazard ratio [HR] 3.28, 95% confidence interval [CI] 1.62–6.62, p = 0.001). This
Hazard ratio is slightly larger, but comparable to dividing this cluster into WHO grade II versus WHO grade III/IV (HR 2.01, 95% CI 1.06–4.02, p = 0.036).
P values determined using Cox proportional hazard regression
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WHO grading of diffuse gliomas that better predict clin-
ical outcome. On the molecular side, we present data in
this study supporting prognostic heterogeneity within
major diffuse glioma clusters, which in some aspects is
identified by conventional grading, but is even better iden-
tified by an additional set of molecular markers. These re-
sults provide evidence of the utility for ‘molecular grading’
within major subgroups of diffuse gliomas.
Along with reflecting changes in WHO classification
of diffuse gliomas, some patterns of genetic alterations
become readily apparent by this visualization tool, as
was the case for the bimodal age distribution of the
IDH-mutant, and 1p/19q-codeleted Oligodendroglioma
cluster (Fig. 4) and cluster-specific gene amplifications
(Fig. 5). For example, the size of dots, representing the
amount of genetic alterations in a single sample as
shown in Fig. 1, demonstrates the amount of genetic
variation within clusters. The IDH-mutant, and 1p/19q-
codeleted oligodendroglial tumor cluster is enriched for
the smallest points, indicating a genomically stable
group, while the astrocytic glioma/glioblastoma, IDH-
wildtype cluster has the largest points, representing
more frequent mutations and copy number aberrations
in this more aggressive type of glioma. The group with
an intermediate clinical outcome, the astrocytic glioma/
glioblastoma, IDH-mutant cluster, has the most variabil-
ity in dot size, indicating a genomically more heteroge-
neous group. Perhaps in diffuse gliomas, the IDH
mutational pathway of oncogenesis leads to some gen-
omic stability with 1p/19q codeletion further potentiat-
ing relative genomic stability.
With the TCGA dataset, there are current limitations
with regards to placement of some diffuse glioma histo-
logic subtypes on the 2D Oncoscape map. For example,
it is not clear where gemistocytic astrocytoma, IDH-
mutant (a histological variant of diffuse astrocytoma,
IDH-mutant) [23], would be distributed in the astrocytic
glioma/glioblastoma, IDH-mutant cluster, or if regional
clustering would occur at all. In addition, there are glio-
blastoma, IDH-wildtype histological variants that have
an unknown cluster distribution, either because of lack
of annotation or lack of sequencing. These glioblastoma
variants include giant cell glioblastoma, gliosarcoma,
and epithelioid glioblastoma [23]. They are presumed to
exist in the IDH-wildtype cluster, but any specific
regionality or grouping is unknown. Gliosarcoma and
giant cell glioblastoma tend to lack EGFR amplification,
and are therefore likely not associated with EGFR-ampli-
fied cases in the IDH-wildtype cluster. Epithelioid glio-
blastomas harbor the BRAF-V600E mutation in about
half of all cases [23]. There are eleven cases of diffuse
gliomas with BRAF single nucleotide alterations present
exclusively in the IDH-wildtype cluster (not shown),
however, they are of various grades (2 WHO grade II; 2
WHO grade III; 4 WHO grade IV; 2 not graded) and ap-
pear not to group together. Therefore, it will take in-
creased numbers of properly annotated glioblastoma
histological subtypes to resolve their spatial distribution,
if any. Along these lines, the current datasets for brain
tumors in Oncoscape are limited to the diffuse gliomas
from the TCGA. Additional efforts are necessary to
characterize other CNS tumor types (other glial, epen-
dymal, glioneuronal, pineal, embryonal, meningeal, etc.)
by multidimensional scaling analysis in order to com-
pare molecular genetic structures and make associa-
tions between and amongst histologically disparate
brain tumor types.
Conclusions
The ability to visualize brain tumor datasets in 2D space
relative to pathologic diagnosis and molecular alterations
with tools such as Oncoscape, affords the possibility of
using such a tool as a reference point for clinical utility.
On the clinical side, molecular information derived from
a specific patient’s surgical material can be queried in
the reference dataset, and survival and treatment
Fig. 8 Prognostic validation of The Cancer Genome Atlas (TCGA) cluster-derived molecular subtypes in a large cohort from the German Glioma
Network (GGN). a Bar graph showing normalized median overall survival (OS) compared to baseline with similar trends for TCGA and GGN datasets.
b Linear regression analysis demonstrating equivalent ratio of normalized molecular subtype OS between TCGA and GGN data sets
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strategies of similar patients can inform prognosis and
risk-stratification in real-time. This may have further
utility in interdisciplinary settings such as neuro-
oncology tumor boards, where management decisions
are discussed and planned. This has the potential to ease
the decision making process and contribute to the appli-
cation of precision medicine for individual patients.
Given the time and financial constraints that can be as-
sociated with whole exome/genome 2D mapping for an
individual patient, a more limited or targeted analysis
may be more prudent. In this setting, cluster-derived
molecular subtypes as the ones described in this study
(W1–4, M1–3), may be a more appropriate way to risk-
stratify in a time-sensitive and cost-effective manner.
Beyond brain tumors, Oncoscape can be used to
visualize and analyze additional cancer datasets for diag-
nostic and translational purposes. All 33 TCGA datasets
encompassing several organ systems are available for
analysis in Oncoscape. Perhaps 2D molecular analysis of
this type can help visualize distinct clusters of various
other cancers, and help to push the solid tumors from
these organ systems to move into integrated diagnoses
and risk-stratification, similar to that of neoplasms of
the central nervous system.
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